Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Conagra Brands Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Conagra Brands Inc trades at $13.85 (market cap $6.62B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 10.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CAG | |
|---|---|---|
Market Cap | $39.89B | $6.62B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $20.02 |
52-Week Low | $278.09 | $12.58 |
Enterprise Value | $38.15B | $13.89B |
Dividend Yield | — | 10.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Conagra Brands (CAG) trades at $13.83, up 3.52% today but remains near its 52-week lows with a bearish technical outlook. The stock shows mixed fundamentals with a negative net income margin of -0.39% despite recent revenue stabilization around $11.6B. Analyst sentiment is cautious with 62.5% hold ratings, while recent news highlights concerns about dividend sustainability given the company's 10%+ yield and elevated debt levels.
CAG presents a high-risk opportunity with its deeply discounted valuation (P/E 10.06, P/B 0.81) and substantial dividend yield, but faces significant headwinds including declining earnings, high leverage, and competitive pressures in the consumer staples sector. The upcoming Q2 2026 earnings report on July 15 will be critical for confirming operational turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
